Current Topics in Medicinal Chemistry, Volume 4, No. 11, 2004
Contents
LPS Signal Transduction:
The Picture is Becoming More Complex Pp.1115-1126
Endotoxins:
Relationships between Structure, Function, and Activity Pp.1127-1146
Klaus
Brandenburg and Andre Wiese
Inhibition of
Endotoxin Response by Synthetic TLR4 Antagonists Pp.1147-1171
Lynn
D. Hawkins, William J. Christ and Daniel P. Rossignol
Endotoxin
Neutralizing Peptides Pp.1173-1184
Roman
Jerala and Massimo Porro
The Search for
Molecular Determinants of LPS Inhibition by Proteins and Peptides Pp.1185-1201
Primoz
Pristovsek and Jurka Kidric
Abstracts
[Back to top] LPS
Signal Transduction: The Picture is Becoming More Complex
Sander H. Diks, Dick J. Richel and Maikel P.
Peppelenbosch
Lipopolysaccharide (LPS) is the principal initiator of septic shock and it is to a large extent responsible for post-operative mortality. The use of antibiotics is still the most successful therapy against infection that may lead to sepsis and septic shock. With the advent of antibiotic resistant strains like MRSA the usefulness of conventional antibiotics is declining and new treatment strategies for LPS-mediated septic shock are called for. In this review we discuss the molecular mechanisms that are involved in the recognition of LPS and in the initiation of an immune response. Furthermore, we also review the recent insights in the signal transduction including receptor clustering and signalosome activation. Further insight into LPS-dependent signal transduction will assist the development of novel rational therapy.
[Back to top] Endotoxins:
Relationships between Structure, Function, and Activity
Klaus Brandenburg and Andre Wiese
Molecules of endotoxin (lipopolysaccharides, LPS), forming a unique molecular class with peculiar physicochemical properties, impart a very important role in the formation and function of the outer membrane (OM). The latter is strictly asymmetric with the LPS monolayer forming the outer leaflet and the phospholipid (PL) monolayer forming the inner leaflet. Thus, the OM builds a functional lipid environment for the OM proteins (Omp’s, porins) and the LPS layer is the first locus of interaction of the bacterial cells with components of the host’s immune system, . Therefore its physical state and biochemical parameters (such as the fluidity of the lipid A acyl chains and the backbone charge density) essentially influence the defense of bacteria against the attack of the human immune systems such as the complement and antimicrobial peptides/proteins. LPS, released from the bacterial cell, is responsible for a variety of biological effects which can be ascribed to the unique structural features of LPS- the three-dimensional supramolecular structure and the intramolecular conformation - which are essential determinants of the bioactivity of endotoxins. Here, the physico-chemical parameters which are important on the one side for the function of the OM and on the other side for the activity of isolated LPS are reviewed.
[Back to top] Inhibition
of Endotoxin Response by Synthetic TLR4 Antagonists
Lynn D. Hawkins, William J. Christ and Daniel P.
Rossignol
Endotoxin, from the outer membrane of Gram-negative bacteria, has been implicated as the etiological agent of a variety of pathologies ranging from relatively mild (fever) to lethal (septic shock, organ failure, and death). While endotoxin (also known as lipopolysaccharide or LPS) is a complex heterogeneous molecule, the toxic portion of LPS (the lipid A portion) is relatively similar across a wide variety of pathogenic strains of bacteria, making this molecule an attractive target for the development of an LPS antagonist. Research over the past fifteen years focused on the design of various lipid A analogs including monosaccharide, acyclic and disaccharide compounds has lead to the development of E5564, an advanced, unique and highly potent LPS antagonist. E5564 is a stable, pure LPS antagonist that is selective against endotoxin-mediated activation of immune cells in vitro and in animal models. In Phase I clinical trials, we have developed an ex vivo endotoxin antagonism assay that has provided results on pharmacodynamic activity of E5564 in addition to the more typical safety and pharmacokinetic evaluations. Results from these assays have been reinforced by analysis of in vivo antagonistic activity using a human endotoxemia model. Results from all of these studies indicate that E5564 is an effective in vivo antagonist of endotoxin, and may prove to be of benefit in a variety of endotoxin-mediated diseases. This review discusses the evolution of synthetic LPS antagonists with emphasis on the SAR and development of E5564 and its precursors.
[Back to top] Endotoxin
Neutralizing Peptides
Roman Jerala and Massimo Porro
Neutralization and sequestration of bacterial lipopolysaccharide which plays a key role in gram-negative sepsis is required to block the progression of sepsis at early stages in addition to destroying bacteria. Many of the host defense peptides which have antimicrobial activity are also able to bind to and neutralize LPS, however, these two activities do not necessarily correlate. Due to its toxicity application of polymyxin B as the prototype of LPS neutralizing peptide is limited to topical applications and extracorporeal removal of endotoxin. Development of novel endotoxin neutralizing peptides without the toxicity of polymyxin B have been based on the natural host defense peptides, fragments of LPS binding proteins and engineered peptides. Neutralization of LPS can be achieved through several different peptide fold motifs, which are reviewed in this article. Endogenous host defense peptides, fragments of endotoxin-binding proteins and synthetic anti-endotoxin peptides fold into a-helical, b-hairpin, extended and compact conformations without regular secondary structure. In animal models many of the peptides have demonstrated good in vitro and in vivo endotoxin neutralizing activity but up to now none of the peptides has been approved for clinical application with an anti-endotoxin indication. Recent developments include preparation of novel types of endotoxin neutralizing compounds such as peptides modified by lipophilic moieties and non-peptidic molecules, particularly lipopolyamines and on the other hand additional medical applications such as extracorporeal endotoxin removal, targeting to inflammation sites or endotoxoid based vaccines.
[Back to top] The Search for Molecular
Determinants of LPS Inhibition by Proteins and Peptides
Primoz Pristovsek and Jurka Kidric
Lipopolysaccharide (LPS) induced Gram-negative sepsis and septic shock remain lethal in up to 60 % of cases, and LPS antagonists that neutralize its endotoxic action are the subject of intensive research. The molecular motifs of specific binding of LPS by antiendotoxin proteins and peptides may lead to an understanding of LPS action at the atomic level and provide clues for the development of new immunomodulatory compounds for use as therapy in the treatment of Gram-negative bacterial sepsis. The interaction of LPS with its cognate binding proteins has been structurally elucidated in the single case of the X-ray crystallographic structure of LPS in complex with the integral outer membrane protein FhuA from E. coli K-12 (Ferguson et al., Science 1999, 282, 2215). This structure and other known structures of LPS binding proteins have been used to propose a common binding motif of LPS to proteins. Another independent source of structural information are solution structures of peptides in complex with LPS that can be determined using the transferred NOE effect. The molecular mechanisms of biological activity of bacterial endotoxins can additionally be probed by theoretical means. The growing structural knowledge is opening pathways to the design of peptides or peptidomimetics with improved antiendotoxin properties.